About Metsera
Metsera is a publicly listed company based in New York (United States) founded in 2022, and was acquired by Pfizer in September 2025. Biopharmaceuticals for obesity and metabolic diseases are developed. Metsera has raised $505 million across 2 funding rounds from investors including Fidelity Investments, Pfizer and T. Rowe Price. The company has 81 employees. Its chief executive, as recorded, is Clive Meanwell. Its website metsera.com draws about 23 thousand monthly visits. Its focus areas include Life Sciences, Obesity, Drugs and GLP-1 Based. Its legal entity is METSERA, INC. Its competitors include Carmot, Kailera and Viking Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Metsera was founded in 2022 and is headquartered in New York, United States. Operations center on the biopharmaceutical sector, where a portfolio of treatments for obesity and metabolic diseases is advanced. New strategies are unlocked through scalable, sustainable, and personalized interventions aimed at weight loss, maintenance, and disease prevention. Focus remains on evidence-based approaches to address these health challenges.
- Headquarters New York, United States
- Employees 81
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website metsera.com
- Acquired by Pfizer (Sep 2025)
- Legal Name Metsera, Inc.
- Net Profit-$209.13 M (USD)-343.01as on Dec 31, 2024
- EBITDA-$134.39 M (USD)-229.52as on Dec 31, 2024
- Total Equity Funding$505M (USD)
in 2 rounds
- Latest Funding Round$215M (USD), Series B
Nov 2024
- InvestorsFidelity Investments
& 16 more
- Employee Count81
- Acquired byPfizer
(Sep 2025)
Funding Insights of Metsera
Metsera has successfully raised a total of $505M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $215 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $505M
- Total Rounds 2
- Last Round Series B — $215M
- First Round $290M
(Apr 2024)
- Investors Count 16
All 2 funding rounds of Metsera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $215M | Series B | – | Wellington, Venrock | |
| Apr 2024 | $290M | Series A | – | Arch Venture Partners |
17 investors in total: 17 institutional.
Investors in Metsera
Metsera has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pfizer and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm focused on growth-stage companies | alphawaveglobal.com | New York, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Investment management services are offered by Newpath Partners. | newpath.partners | Boston, United States | ||
Investments in healthcare companies are made by SymBiosis. | symbiosis.vc | Bentonville, United States |
Investor details for Metsera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Metsera
1 people are tracked at Metsera (1 in leadership); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
Clive Meanwell | CEO | Leadership |
Complete people profiles for Metsera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Metsera
Metsera is a publicly listed company on the NASDAQ with ticker symbol MTSR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jan 2025
- Listed onNASDAQ: MTSR
- Listed entityMetsera, Inc.
- Exchange sectorHealth technology
- ISINUS59267L1070
- Share price$70.50 (-0.35% on the day) · 2025-11-14
- Market capitalisation$7.43B
- EPS (diluted, trailing year)$-2.99
- Volume (last session)27,908,881
- Analyst consensusNeutral
Financials of Metsera
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$209.1M | -$134.4M |
Detailed financial statements for Metsera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Metsera
5 dated milestones of Metsera across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Metsera is founded.
- Funding First funding round of $290.0M.
- Funding Latest funding round, Series B, of $215.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Pfizer.
Competitors of Metsera
Metsera has 3 listed competitors in our database, 3 of them funded. They include Carmot, Kailera and Viking Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| kailera.com | 2024 | Waltham, United States | $1B | Developer of therapies for treating obesity and related conditions | ||
| vikingtherapeutics.com | 2012 | California, United States | $2.5M | 27 | Small molecule therapies for endocrine and metabolic disorders are developed. |
Detailed competitors of Metsera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Metsera
The website of Metsera (metsera.com) receives about 23K visits a month and ranks #750,685 among all websites worldwide, #876 in Biotechnology and Pharmaceuticals.
- Monthly visits23K
▼ 49.4% vs previous month
- Unique visitors19.4K
per month
- Global rank#750,685
among all websites
- Category rank#876
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.6
- Average visit31 sec
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Metsera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| biopharmadive.com | 94% | 680.7K | #208,628 | View details | |
medwatch.com | medwatch.com | 94% | #920,565 | – | |
| pharmaphorum.com | 94% | 128.2K | #451,885 | View details | |
| fiercebiotech.com | 81% | 858.3K | #81,022 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Metsera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Obesity
3 companies that operate in the same segment as Metsera (Obesity) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Metsera
Complete news archive for Metsera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metsera
Metsera was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Metsera is headquartered in New York, United States. It is registered at New York, New York, United States.
Clive Meanwell is the CEO of Metsera, as recorded in our data.
Metsera is a funded company, having raised a total of $505M across 2 funding rounds to date. The company's 1st funding round was a Series A of $290M, raised on Apr 2024.
Metsera has 81 employees.
Metsera was founded in 2022 and is headquartered in New York, United States. Operations center on the biopharmaceutical sector, where a portfolio of treatments for obesity and metabolic diseases is advanced. New strategies are unlocked through scalable, sustainable, and personalized interventions aimed at weight loss, maintenance, and disease prevention. Focus remains on evidence-based approaches to address these health challenges.
Metsera's top competitors include Carmot, Viking Therapeutics and Kailera.
Yes, Metsera is publicly traded on NASDAQ under the ticker symbol MTSR.
Metsera has 17 investors. Key investors include Fidelity Investments, Pfizer, T. Rowe Price, Mubadala, and Janus Henderson Investors.
Metsera operates through Metsera, Inc..
Yes. Metsera was acquired by Pfizer in September 2025.